APA

Thürlimann B., Hess D., Köberle D., Senn I., Ballabeni P., Pagani O., Perey L., Aebi S., Rochlitz C. & Goldhirsch A. (20040701). Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. : Breast cancer research and treatment.

Chicago

Thürlimann Beat, Hess Dagmar, Köberle Dieter, Senn Isabella, Ballabeni Pierluigi, Pagani Olivia, Perey Lucien, Aebi Stefan, Rochlitz Christoph and Goldhirsch Aron. 20040701. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. : Breast cancer research and treatment.

Harvard

Thürlimann B., Hess D., Köberle D., Senn I., Ballabeni P., Pagani O., Perey L., Aebi S., Rochlitz C. and Goldhirsch A. (20040701). Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. : Breast cancer research and treatment.

MLA

Thürlimann Beat, Hess Dagmar, Köberle Dieter, Senn Isabella, Ballabeni Pierluigi, Pagani Olivia, Perey Lucien, Aebi Stefan, Rochlitz Christoph and Goldhirsch Aron. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. : Breast cancer research and treatment. 20040701.